Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 47.9%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 103,200 shares, a growth of 47.9% from the September 15th total of 69,800 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro at the end of the most recent quarter. Institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Trading Up 3.7 %

ALZN stock traded up $0.06 during trading on Friday, hitting $1.66. 118,368 shares of the company traded hands, compared to its average volume of 545,148. The company has a 50-day moving average of $2.19 and a 200-day moving average of $4.57. Alzamend Neuro has a 1 year low of $1.40 and a 1 year high of $33.57.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings results on Wednesday, September 11th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($2.38) by $1.13. As a group, sell-side analysts anticipate that Alzamend Neuro will post -14.27 earnings per share for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.